Guangdong Province Releases List of Urgent Clinical Drugs and Devices for GBA Cities
The medical products administration and health commission of Guangdong province have released a list of...
Sanofi’s Tolebrutinib Earns FDA Breakthrough Designation for Non-Relapsing Secondary Progressive MS
Sanofi (NASDAQ: SNY) has announced that the US Food and Drug Administration (FDA) has granted...
Roche’s cobas 6800/8800 Systems 2.0 Earn CE Certification, Set for US Market Entry
Global healthcare company Roche (SWX: ROG) has announced that its state-of-the-art cobas 6800/8800 Systems 2.0...
ARS Pharmaceuticals’ Neffy Receives Market Filings in Asia-Pacific Region
US-based ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) has announced that market filings for its intranasal epinephrine...
Fujian Cosunter Pharmaceutical’s GST-HG141 Earns Breakthrough Designation for Chronic Hepatitis B
Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436), a China-based pharmaceutical company, has announced that it...
Beijing Conference Outlines 2025 Healthcare Security Goals and 2024 Progress
A national conference on healthcare security was recently held in Beijing, reviewing the achievements of...
Quantum Hi-Tech (ChemPartner) Plans to Raise Over RMB 930 Million in Private Placement
Quantum Hi-Tech (China) Biotechnology Co., Ltd, known as ChemPartner (SHE: 300149), is poised to raise...
AbbVie Acquires Roche’s Nimble Therapeutics to Boost Immunology Pipeline
US pharmaceutical company AbbVie (NYSE: ABBV) has reached an agreement to acquire Swiss pharmaceutical giant...
iFlytek’s Xunfei Healthcare Passes HKEX Hearing for AI-Powered Medical IPO
Xunfei Healthcare Technology Co., Ltd., a subsidiary of China’s leading information technology company iFlytek Co.,...
Innovent Biologics Partners with Eli Lilly for Distribution of Jaypirca in China
China-based Innovent Biologics, Inc. (HKG: 1801) has entered into a significant distribution and promotion agreement...
Accropeutics Gets FDA Green Light for Phase II UC Study of RIPK2 Inhibitor AC-101
Accropeutics Inc., a clinical-stage biotechnology company with operations in New York, US, and Suzhou, China,...
EMA’s CHMP Supports Approval of Eli Lilly’s Omvoh (Mirikizumab) for Crohn’s Disease
The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has recently...
Wepon Medical’s WP107 for Myasthenia Gravis Accepted for FDA Review
Wepon Medical Holding Group Co., Ltd. (SHE: 002082) has announced that the US Food and...
Mabwell Bioscience Plans Secondary Listing in Hong Kong, Secures Funding for Bone Health Project
Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) is set to make a secondary listing on...
Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for Lupus Nephritis Clinical Trial
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it has obtained approval from...
Neusoft Medical Systems and Xiamen University Launch MRI R&D Center Partnership
Neusoft Medical Systems Co., Ltd, a prominent Chinese medical technology company, has signed an agreement...
Neusoft Medical Systems and NMPA Collaborate on AI-Enhanced Drug Administration
Neusoft Medical Systems Co., Ltd, a leading Chinese medical technology company, has announced a strategic...
Grand Pharmaceutical’s STC3141 Sepsis Therapy Completes Phase II Patient Enrollment
China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) has announced the completion of patient enrollment...
Innovent Biologics Initiates Phase I Trial for IBI3009 in Small Cell Lung Cancer and Neuroendocrine Tumors
On December 13, 2024, Innovent Biologics, Inc. (HKG: 1801) registered a Phase I clinical trial...
Huahai Pharmaceutical’s Adalimumab Biosimilar Accepted by China’s CDE for Review
On December 14th, the China National Medical Products Administration’s (NMPA) Center for Drug Evaluation (CDE)...